NPS Pharmaceuticals (NPSP)

[brw]

Great double bottom formed-- watch out!

[LasNubes]

What's up here today?
Anyone have info on the pullback?

[surf1944]

8:30AM NPS Pharm receives orphan designation for Natpara in Europe (NPSP) 31.71 : Co announced that the European Commission has granted orphan drug designation to Natpara (recombinant human parathyroid hormone (rhPTH[1-84]) for the treatment of hypoparathyroidism. Natpara is a bioengineered replacement for endogenous parathyroid hormone (PTH) that NPS has developed for the treatment of hypoparathyroidism, a rare endocrine disorder in which the body produces insufficient levels of parathyroid hormone, a principal regulatory of the body's mineral homeostasis.

[TheFinalCD]

NPS Pharmaceuticals Receives Orphan Drug Designation for Natpara® in Europe










Nps (NASDAQ:NPSP)
Intraday Stock Chart

Today : Friday 3 January 2014
Click Here for more Nps Charts.
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, today announced that the European Commission has granted orphan drug designation to Natpara® (recombinant human parathyroid hormone (rhPTH[1-84]) for the treatment of hypoparathyroidism. Natpara is a bioengineered replacement for endogenous parathyroid hormone (PTH) that NPS has developed for the treatment of hypoparathyroidism, a rare endocrine disorder in which the body produces insufficient levels of parathyroid hormone, a principal regulatory of the body’s mineral homeostasis. Orphan drug designation in the European Union (EU) is given to products that are designed for the diagnosis, prevention or treatment of rare diseases that are life-threatening or chronically debilitating. A disease is defined as rare in the EU if it affects no more than five in 10,000 people.

“We are very pleased that Natpara has received orphan drug status in the EU,” said Francois Nader, MD, president and chief executive officer of NPS Pharmaceuticals. “As a global rare disease biopharmaceutical company, this aligns with our commitment to deliver innovative therapies that transform the lives of patients around the world. Hypoparathyroidism patients face a significant burden of disease given the multitude of physical, cognitive, and emotional symptoms associated with this disorder. Natpara could be the first PTH replacement therapy to treat this condition.”

The company was also granted orphan drug status by the U.S. Food and Drug Administration (FDA) in 2007. The company submitted its U.S. Biologic License Application to FDA in October 2013.

About Hypoparathyroidism

PTH plays a central role in a variety of critical physiological functions, including closely modulating serum calcium and phosphate, regulating renal excretion of calcium and phosphate, activating vitamin D, and maintaining normal bone turnover. In patients with hypoparathyroidism, insufficient levels of PTH lead to low serum calcium, high serum phosphate, increased urinary calcium excretion, and decreased urinary phosphorus excretion. PTH deficiency can also disrupt skeletal homeostasis, leading to bone abnormalities. In addition, patients with insufficient levels of PTH are unable to convert native vitamin D into its active state to properly absorb dietary calcium.

Acute symptoms of hypoparathyroidism are largely due to hypocalcemia and include fatigue, muscle spasms and cramps, tingling, tetany, seizures, brain fog/mental lethargy, anxiety, and depression. In the absence of an approved parathyroid replacement therapy, the standard approach focuses on using high doses of calcium and active vitamin D to increase calcium levels in the blood and reduce the severity of hypocalcemic symptoms. However, balancing the administration of supplements is challenging due to calcium fluctuations and the long-term use of high doses of calcium and vitamin D may lead to serious complications, including long-term renal damage. In addition, because serum phosphate levels are elevated when PTH is missing, increasing serum calcium may lead to irreversible calcium-phosphate deposits in the kidneys, arteries or brain. Further, supplements do not correct the abnormal bone metabolism due to PTH deficiency or enable the activation of vitamin D.

About NPS Pharmaceuticals

NPS Pharmaceuticals is a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide. The company’s lead product, Gattex® (teduglutide [rDNA origin]) for injection is approved in the US for adult patients with Short Bowel Syndrome (SBS) who are dependent on parenteral support. In the EU, teduglutide (trade name: Revestive®) is approved for the treatment of adult patients with SBS; patients should be stable following a period of intestinal adaptation after surgery. Teduglutide is not approved for the treatment of pediatric SBS patients. The safety and efficacy of teduglutide in this population is currently being evaluated in a global registration trial.

NPS has also developed Natpara® (rhPTH [1-84]) for the treatment of hypoparathyroidism and submitted a Biologics License Application to the US Food and Drug Administration in October 2013.

NPS’ earlier stage pipeline includes NPSP795, a calcilytic compound with potential application in rare disorders involving increased calcium sensing receptor activity, such as autosomal dominant hypocalcemia (ADH). NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Janssen Pharmaceuticals, and Kyowa Hakko Kirin. Additional information about NPS is available through its corporate website, http://www.npsp.com.

“NPS,” “NPS Pharmaceuticals,” “Gattex,” “Revestive,” and “Natpara” are the company's trademarks

[sps50]

Thanks. All of sudden NPSP is popular again on no news. I like NPSP, but for this far up in 4 days... why do I sense an MM sucker-dump coming two months before earnings?

[ECole]

Transcript of Conf call- Jefferies-Global-Healthcare-Conference



http://www.earningsimpact.com/Transcript/84633/NPSP/Nps-Pharmaceuticals%2c-Inc----Jefferies-Global-Healthcare-Conference

[sps50]

Tue - dumps took wind out of the sails too many times?"

[surf1944]

8:02AM NPS Pharm reports new data from STEPS 2 support the long term use of gattex; patients on gattex treatment beyond one year continue to achieve clinically meaningful reductions in parenteral support requirements, with some achieving complete independence (NPSP) 29.74 : STEPS 2 is a two-year open-label extension study of 88 adult patients with SBS. Investigators reported that the long-term use of Gattex in patients with SBS resulted in additional, clinically meaningful reductions in the volume and days per week of parenteral support requirements in this extension study.

In addition, 10 of the 13 patients who achieved complete independence from parenteral support were those who received 30 months of Gattex in the 6-month STEPS pivotal study and the 24-month STEPS 2 study. Two patients who received placebo in STEPS and 24 months of Gattex in STEPS 2 and one patient who bypassed STEPS and was enrolled directly into STEPS 2 also achieved independence from parenteral support. No new unexpected safety concerns were observed with long-term Gattex treatment and the product's safety profile remains consistent with the product's label.

The primary objective of STEPS 2 was to study long-term safety and durability of effect in patients who completed, participated in, or qualified for participation in STEPS, a 24-week, placebo-controlled, multi-center, international Phase 3 study of Gattex in adult subjects with SBS. The majority of patients in STEPS 2 achieved and maintained clinically meaningful responses after Gattex treatment. A responder was defined as a subject who achieved a 20 to 100 percent reduction in the volume of parenteral support from baseline.

A higher percentage of patients who received Gattex for 30 months (the Gattex/Gattex group) responded and achieved greater reductions in parenteral support volume and days per week compared with those who received Gattex for 24 months (Placebo/Gattex group and Not-treated/Gattex group). In addition, 33 percent of patients (10/30) who received 30 months of Gattex achieved complete independence from parenteral support. The rates of adverse events of special interest as described in the U.S. Prescribing Information remain consistent.

The most common adverse events were abdominal pain, catheter sepsis, and episodes of decreased weight, nausea, gastrointestinal stoma complications, and abdominal distension.

[sps50]

For all the shares traded, I am surprised how few posters there are on ihub. Charles Cramer must have a robotic following. For minutes after he downs on NPSP, heavy dumps occur. Not once, but several times. I am all for reasonable pps but the latest good news, in a series of good news was not an instant run up but people doing DD over time. Very suspicious...

[surf1944]

8:05AM NPS Pharm: Pivotal study published in the Lancet Diabetes & Endocrinology; Findings confirm the potential of Natpara as a parathyroid hormone replacement therapy for adult hypoparathyroidism (NPSP) 34.79 : Co announced that its pivotal Phase 3 study of Natpara, known as REPLACE, was published online in The Lancet Diabetes & Endocrinology. Study findings underscore Natpara's potential as a replacement therapy for endogenous parathyroid hormone (PTH) in hypoparathyroidism, a rare endocrine disorder characterized by insufficient production of PTH, a principal regulator of the body's mineral homeostasis.

"Managing hypoparathyroidism can be challenging because it is limited to controlling symptoms, which does not address the underlying cause of the disorder and may have deleterious effects on major organs,"

REPLACE, a 24-week international phase 3 study of efficacy and safety of daily subcutaneous Natpara in 134 patients with hypoparathyroidism, is the largest randomized, placebo-controlled clinical trial conducted to date in patients with this rare and complex endocrine disorder. Patients were randomized 2:1 to 50 g subcutaneous once daily Natpara or placebo. In the study active vitamin D and oral calcium were progressively reduced, while Natpara could be titrated up from 50 to 75 and then 100 g.

Patients self-administered treatment for 24 weeks and were then followed for four additional weeks after the completion of the treatment phase. 53 percent of Natpara-treated patients achieved the primary endpoint by decreasing doses of oral calcium and active vitamin D by 50 percent or more, while maintaining serum calcium levels by the end of the treatment phase. In contrast, only 2 percent of the placebo group (P<0.001) met the primary endpoint.

Among secondary endpoints, by Week 24, 43 percent (36/84) of patients treated with Natpara were able to achieve independence from active vitamin D therapy and required only 500 mg/day or less of oral calcium, as compared to five percent (2/37) of patients treated with placebo (p<0.0001).

[surf1944]

8:14AM NPS Pharm reports Gattex Steps 2 study to be presented at american college of gastroenterology meeting; supplemental new drug application submitted for STEPS 2 data (NPSP) 33.49 : Co reported that results from the company's STEPS 2 study of GATTEXin patients with Short Bowel Syndrome were accepted for presentation at the American College of Gastroenterology (ACG) Annual Scientific Meeting and Postgraduate Course in San Diego, California, October 11-16, 2013. STEPS 2 was a two-year open-label extension study that involved 88 adult SBS patients with short bowel syndrome.

The abstract entitled, "Long-term Safety and Efficacy of Teduglutide for the Treatment of Intestinal Failure Associated with Short Bowel Syndrome: Final Results of the Steps-2 Study, a 2-year, Multicenter, Open-label Clinical Trial" by Schwartz et al. is also being recognized as an ACG Presidential Poster Award recipient.

The ACG Educational Affairs Committee identifies the most highly ranked abstracts selected for the poster sessions in each category and acknowledges their achievement with this award. The company also reported that it has submitted a Supplemental New Drug Application to the FDA for Gattex revising the product label to include long-term data from STEPS 2.

Gattex is indicated for the treatment of adult patients with short bowel syndrome who are dependent on parenteral support. Significant reductions in mean PN/IV infusion volume from baseline to end of treatment were seen in the Phase 3 studies of Gattex. In addition, some patients were able to achieve independence from PN/IV support during these trials. The most common side effects of Gattex include stomach area (abdomen) pain or swelling, skin reaction where the injection was given, nausea, headache, cold or flu like symptoms, vomiting, and holding too much fluid in the body.

NPS is preparing to engage in the pricing and reimbursement processes in key European countries with the goal of commercially launching Revestive in Europe in the first half of 2014. Teduglutide has orphan drug designation for the treatment of SBS from the European Medicines Agency and the FDA.

[ECole]

Wedbush-2013-Life-Sciences-Management-Access-Conference Presentation

read here
http://www.earningsimpact.com/Transcript/82855/NPSP/NPS-Pharmaceuticals%2c-Inc----Wedbush-2013-Life-Sciences-Management-Access-Conference

[gixxer11]

Yep - boy did I miss this one , was on my watch list forever too..

[ECole]

Interesting remarks at Jefferies Healthcare Conference

Read here

[DrTooth]

What did Long-shareholders do with their old NPSP shares; the penny-stock?
I've been out of the loop for several months. The old NPSP is gone, why and what happened to the old stock?

[NASDAQ2020]

Will this stock ever do any thing?

[WID]

NPS Pharmaceuticals Prices Public Offering of Common Stock at No Discount

NPS Pharmaceuticals, Inc. (NPSP) today announced the pricing of an underwritten public offering of 6,000,000 shares of its common stock at a price of $14.53 per share to the public. All of the shares are being sold by NPS. The gross proceeds to NPS from this offering are expected to be approximately $87.2 million, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by NPS. The offering is expected to close on or about May 24, 2013, subject to the satisfaction of customary closing conditions.

http://finance.yahoo.com/news/nps-pharmaceuticals-prices-public-offering-215700345.html

[starbuxsux]

$NPSP - NPS Pharmaceuticals Announces Proposed Public Offering of 6,000,000 Shares of its Common Stock

May 20, 2013 16:21:00 (ET)


BEDMINSTER, N.J., May 20, 2013 (BUSINESS WIRE) -- NPS Pharmaceuticals, Inc. , today announced that it has commenced an underwritten public offering of 6,000,000 shares of its common stock. All of the shares in the offering are to be sold by NPS.

J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC are acting as joint book-running managers for the proposed offering. NPS intends to grant the underwriters a 30-day option to purchase up to 900,000 additional shares of its common stock to cover over-allotments, if any. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (the "SEC") and is effective. A preliminary prospectus supplement relating to the offering has been filed with the SEC. Copies of the preliminary prospectus supplement and accompanying prospectus may be obtained from the offices of J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (Telephone number 866-803-9204); or Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014 (Telephone number 866-718-1649, e-mail: [e-mail]).

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About NPS Pharmaceuticals

NPS Pharmaceuticals is a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide. The company's lead product, Gattex(R) (U.S.)/Revestive(R) (EU) (teduglutide [rDNA origin]) for injection is approved for adult Short Bowel Syndrome (SBS) patients who are dependent on parenteral support. NPS is also developing Natpara(R) (rhPTH [1-84]) for the treatment of adult hypoparathyroidism and, subject to the resolution of certain manufacturing issues, expects to submit its Biologic License Application (BLA) to the FDA in 2013.

NPS's earlier stage pipeline includes two calcilytic compounds, NPSP790 and NPSP795, with potential application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia (ADH). NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Janssen Pharmaceuticals, and Kyowa Hakko Kirin. Additional information about NPS is available through its corporate website, http://www.npsp.com .

"NPS," "NPS Pharmaceuticals," "Gattex," "Natpara," "Revestive," "Preotact," and "NPS Advantage" are the company's trademarks. All other trademarks, trade names or service marks appearing in this press release are the property of their respective owners.

Disclosure notice

Statements made in this press release, which are not historical in nature, constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements are based on our current expectations and beliefs regarding the completion of the proposed public offering. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, risk and uncertainties related to whether or not we will be able to raise capital through the sale of shares of common stock, the final terms of the proposed offering, market and other conditions, the satisfaction of customary closing conditions related to the proposed public offering and the impact of general economic, industry or political conditions in the United States or internationally. There can be no assurance that we will be able to complete the proposed public offering on the anticipated terms, or at all. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. Additional risks and uncertainties relating to the proposed offering, NPS and our business can be found under the heading "Risk Factors" included in the preliminary prospectus supplement related to the proposed offering filed with the SEC on or about the date hereof, and in other filings we periodically make with the SEC. In addition, the forward-looking statements included in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

http://cts.businesswire.com/ct/CT?id=bwnews&sty=20130520006413r1&sid=cmtx4&distro=nx

SOURCE: NPS Pharmaceuticals, Inc.


NPS Pharmaceuticals, Inc.
Susan M. Mesco, [phone]
[e-mail]

[surf1944]

8:08AM NPS Pharm beats by $0.04, misses on revs (NPSP) 13.57 : Reports Q1 (Mar) loss of $0.09 per share, $0.04 better than the Capital IQ Consensus Estimate of ($0.13); revenues rose 10.9% year/year to $25.4 mln vs the $27.53 mln consensus.

NPSP previous financial guidance for 2013 remains unchanged. In 2013, NPSP continues to expect its operating expenses, including the impact of share-based compensation and excluding cost of goods sold, to be between $135 and $145 million.
NPSP recently met with the U.S. Food and Drug Administration (FDA) to review its development strategy for Gattex in pediatric SBS. Based on this meeting, the company plans to meet with the European Medicines Agency to discuss a global strategy for the development of Gattex in the pediatric setting.
"By regaining the ex-U.S. rights for teduglutide and PTH 1-84 from Takeda, we have established NPS as a global orphan disease company with commercial products in the U.S. and in Europe. In parallel, we have made good progress toward resolving the current fill-finish issues for our second potential commercial orphan drug, Natpara. We expect to file Natpara's U.S. Biologic License Application for hypoparathyroidism in the second half of this year."

[WID]

I dont trust Ford Equity Research at all.

[KentClark]

Ford equity research has NPSP as a strong sell?
Is NPSP looking at a pull back?

[digital]

nps drugs can be distributed with appa process both valuable pharmaceuticals IMO

[surf1944]

2:16AM NPS Pharm and Takeda (TKPYY) revise agreements and NPS re-gains full worldwide rights to Teduglutide and recombinant human parathyroid hormone 1-84 (NPSP) 9.04 : NPS Pharmaceuticals (NPSP) and Takeda Pharmaceutical (TKPYY) announce that NPS has re-gained the full worldwide rights to teduglutide and recombinant human parathyroid hormone 1-84. NPS licensed the commercial rights to Preotact and Revestive in 2004 and 2007, respectively, for territories outside of North America to Nycomed, which was acquired by Takeda in 2011.

NPS will have worldwide rights to develop and commercialize teduglutide and PTH 1-84. Takeda will also assign to NPS its assets related to the two products, including all of its active pharmaceutical ingredient inventory and information related to the products' continued development, manufacture, and commercialization, including life cycle management assets. Takeda will receive NPS common stock valued at $50 mln. Takeda will also earn a milestone payment in the first calendar year that combined worldwide net sales of both products exceed $750 mln. NPS has the option of making this milestone payment in the amount of $30 mln, in cash or NPS common stock.

[Penny Roger$]

NPSP nice call imo.

[surf1944]

NPSP back on bottom reversal watch...

[biocqr]

Orphan Drugs & Value Propositions: Randy Explains
Make a comment
By Ed Silverman // January 17th, 2013 // 11:16 am

Earlier this month, NPS Pharmaceuticals announced that the price for its Gattex treatment for short-bowel syndrome would cost $295,000 a year, roughly three times what Wall Street had expected. This marked the fourth time in the past year that an orphan drug was approved and the price per patient was set at more than $200,000 annually. The move highlighted a growing debate about the calculations used for developing new medications designed for small patient populations and the ability of the healthcare system to afford these treatments and accommodate patients. We spoke with Randy Vogenberg, a principal at the Bentelligence consulting firm, which specializes in benefits consulting and strategic decision making, about the implications for drug makers and payers…

Pharmalot: Why are we seeing this kind of pricing?
Vogenberg: I think part of the reason is that we’re dealing with smaller patient populations than in the past and that’s the typical situation. There are hundreds instead of however many tens of thousands of patients and then we’re spreading cost among a smaller group. So unit costs rise dramatically. And there’s a Catch 22 around pricing – which is a little unique around specialty (drugs). You have a smaller number (of patients) and charging a higher price, so there’s a higher percentage of patients who can’t afford it. This means there’s greater need for unrestricted grants and patient assistant programs. So as a company, you end up paying more for your own product than in the older, traditional marketplace.

more...
http://www.biotechinvestorsnetwork.com/#!featured-article/c17ob

[charliewho]

Holy form 4's

[onkelhubert]

holy s..t what was that? short covering?

[kitchenboy]

do not understand the shorting going on. why the fall. thoughts? Am in it big for the potential drug approval end of dec

[spottrader]

haha Sheff not sure what to think...well...he did buy it at the highs.

[spottrader]

nice little dump today. shocking. lol

[spottrader]

another big block sell today...happening daily.

[spottrader]

CMF going neg here. shocking. lol

[spottrader]

writing on the wall here. don't get caught holding the bag.

[oregon 1]

We are going to get back to 10 today.

[spottrader]

$NPSP short beauty here. Thanks $heff

[spottrader]

$heff buying at highs here. lol. so he says. notice the trend.

[spottrader]

$heff forgot to mention a director also sold everything (140k shares) at around the same price.

NPSP..$10.13 Definitely back on my radar again for an entry.

Nice to see buying before the PDUFA date. Insider buying on 11/15. Stock has been on a run since then. Director bought 11,000 shares at $9.09. PDUFA date of 12/30/12.

http://www.sec.gov/Archives/edgar/data/890465/000147406412000066/xslF345X03/edgar.xml

[spottrader]

not sure why folks are rushing to buy this yet, especially, $heff. Chart clearly wants 9.50 at least before move upwards.

[LasNubes]

Looking to get back in again today on any dip in price.
This looks good for approval 12/30

[surf1944]

8:07AM NPS Pharm announces publication of pivotal Phase 3 study of Gattex in short bowel syndrome-intestinal failure patients; Gattex is effective and well-tolerated (NPSP) 9.99 : Co announced that its Phase 3 study of Gattex, a novel analog of glucagon-like peptide 2, has been published online in the peer-reviewed journal, Gastroenterology, the official journal of the American Gastroenterological Association. The 24-week study, known as STEPS, shows that Gattex is effective and well-tolerated in reducing parenteral support volume and number of infusion days in short bowel syndrome-intestinal failure patients.

Researchers performed a 24-week study of patients with SBS-IF who were given either daily subcutaneous dosing of 0.05 mg/kg teduglutide or placebo.
Parenteral support was reduced if 48-hour urine volumes exceeded baseline values by 10 percent.
The primary efficacy endpoint was defined as the number of patients who achieved a 20 to 100 percent reduction in weekly PS volume, from baseline, at Weeks 20 and 24. There were significantly more responders in the teduglutide group (27 of 43) than the placebo group (13 of 43, p=.002). At Week 24, patients who received teduglutide experienced an average 4.4 liter reduction in weekly PS volume from a baseline of 12.9 liters. Patients who received placebo experienced an average 2.3 liter reduction from a baseline of 13.2 liters.
After completing 24 weeks of treatment, 54 percent (21 of 39) of teduglutide-treated patients were able to reduce the number of infusion days per week by one or more days, compared to 23 percent (9 of 39) of those treated with placebo (p=0.005).
The distribution of treatment-emergent adverse events that led to study discontinuation was similar between patients given teduglutide (n=2) or placebo (n=3). The most commonly reported adverse events were gastrointestinal-related and appear to be consistent with the pharmacological effects of the drug.

[gixxer11]

Watch for stop loss triggers - bio tech can get extremely crazy

[jaybird5]

I don't understand y the stock is down

[gixxer11]

Np bud - traded very strange for good news after ADCOM

No buyers at all to push the profit taking up IMO..

Will be watching 2 morro - for stop loss triggers within the 1st 15 min

[Globaltrnr]

Thnx gixxer .. will keep on radar .. may short it tomorrow ..

[gixxer11]

Sell the news - same thing with arna except bigger pop ..

The other thing Is that it might of been already priced in..

Shorts will kill it 2 morro - I can almost bet 99% this will be very red 2 morro

[Globaltrnr]

If was approved then why is it down??

[gixxer11]

NPSP - is going to get slaughter 2 morro

[gixxer11]

Sorry guys - wow

[gixxer11]

NPSP RESUMES TRADING - 4:20 PM